BMS-931699

DRUG3 trials

Sponsors

Bristol-Myers Squibb

Conditions

HealthyLupusSjögren's Syndrome

Phase 1

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

TerminatedNCT03058822

Bristol-Myers SquibbHealthy

Start: 2017-01-25End: 2017-03-30Updated: 2017-12-20

Phase 2

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

CompletedNCT02265744

Bristol-Myers SquibbLupus

Start: 2014-11-13End: 2017-11-30Updated: 2019-10-07

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

TerminatedNCT02843659

Bristol-Myers SquibbSjögren's Syndrome

Start: 2016-10-18End: 2017-07-24Updated: 2018-10-04